BMS' Opdivo Gets CHMP Backing For Expanded European Label
This article was originally published in The Pink Sheet Daily
Use for previously treated advanced renal cell carcinoma in adults as well as previously treated metastatic non-squamous non-small cell lung cancer, regardless of PD-L1 expression, is recommended by EMA Committee for Medicinal Products for Human Use.
You may also be interested in...
Onxeo acquires signal-interfering DNA repair technology for its orphan oncology focus. Sanofi returns auto-injector product to kaleo after product recall.
Phase Ib results for PD-L1/CTLA-4 combination look competitive, but editorial questions whether the company has moved too fast with development in response to intense market pressure.
Leading sponsors of PD-1/L1 checkpoint inhibitors looked back on a string of successes and ahead toward the future for combinations with a wide range of other targets during full-year earnings calls.